

Plasma glucagon-like peptide (GLP) (7-36) amide response to low versus high glycaemic index drinks in Type II diabetic subjects and non-diabetic controls.

Submission date

30/09/2004

Recruitment status

No longer recruiting

Registration date

30/09/2004

Overall study status

Completed

Last Edited

10/03/2011

Condition category

Nutritional, Metabolic, Endocrine

☐ Prospectively registered

☐ Protocol

☐ Statistical analysis plan

☒ Results

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Miss Joanne Milton

Contact details

Nutrition and Dietetics Department

Imperial College

Hammersmith Campus

London

United Kingdom

W12 0HS

+44 (0)208 383 5802

JMilton@hhnt.org

Additional identifiers

Protocol serial number

N0016132030

Study information

Scientific Title

Study objectives

1. To investigate the effects of drinks of differing glycaemic index (GI) on plasma GLP-1 concentrations and subsequent metabolic responses to a meal.
2. To determine if a low GI drink will cause a greater increase in postprandial GLP-1 concentrations and result in improved metabolic response compared to a high GI drink or water at a subsequent meal.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Nutritional, Metabolic, Endocrine: Diabetes

Interventions

Not provided at time of registration

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Diet is the first line treatment for Type 2 diabetes, however the optimal diet to promote good glycaemic control is still debated. GLP-1 is being investigated as an agent for the treatment of diabetes, however it has its shortcomings due to its short half life in humans. A specific food that could be consumed before a meal to stimulate release of GLP-1 and thus improve glycaemic control would be highly beneficial to patients, and potentially have fewer side effects and be less invasive than subcutaneous administration of the hormone.

Key secondary outcome(s)

Not provided at time of registration

Completion date

09/09/2007

Eligibility

Key inclusion criteria

1. 12 diabetics and 12 healthy volunteers
2. Ages 30-65

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

10/09/2003

Date of final enrolment

09/09/2007

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Nutrition and Dietetics Department

London

United Kingdom

W12 0HS

Sponsor information

Organisation

Department of Health

Funder(s)

Funder type

Government

Funder Name

Hammersmith Hospital NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2007		Yes	No